Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Akero Therapeutics, Inc. (NASDAQ: AKRO) to Novo Nordisk A/S is fair to Akero shareholders. Under the terms of the proposed transaction, Akero shareholders will receive $54.00 per share in cash, and a non-transferable Contingent Value Right entitling its holder to receive a cash payment of $6.00 per share upon full U.S. regulatory approval of efruxifermin by June 30, 2031.

Halper Sadeh encourages Akero shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com.

The investigation concerns whether Akero and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Akero shareholders; (2) determine whether Novo Nordisk is underpaying for Akero; and (3) disclose all material information necessary for Akero shareholders to adequately assess and value the merger consideration.

On behalf of Akero shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits. We would handle the action on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251009325914/en/